Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.47 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881448 | 0.93 | KCNK3 (0.54) | MEN1KMT2AKCNK3LMNANPC1 | |
| SCHEMBL1878675 | 0.92 | LMNA (0.58) | MEN1KMT2AKCNK3ADORA2ALMNA | |
| SCHEMBL1882463 | 0.92 | NPC1 (0.54) | MEN1KMT2AKCNK3LMNATP53 | |
| SCHEMBL1877650 | 0.90 | MEN1 (0.53) | MEN1KMT2AKCNK3LMNATP53 | |
| SCHEMBL1875206 | 0.89 | KCNK3 (0.56) | MEN1KMT2AKCNK3LMNATP53 | |
| SCHEMBL1877416 | 0.89 | LCK (0.58) | MEN1KMT2AKCNK3LMNATP53 | |
| SCHEMBL1883977 | 0.87 | SMN1; SMN2 (0.57) | MEN1KMT2AKCNK3LMNATP53 | |
| SCHEMBL1883271 | 0.86 | MEN1 (0.57) | MEN1KMT2AKCNK3LMNATP53 | |
| SCHEMBL1875756 | 0.86 | PPARG (0.53) | MEN1KMT2ALMNATP53NPC1 | |
| SCHEMBL1879361 | 0.86 | HSP90AB1 (0.60) | MEN1KMT2AKCNK3LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947696-B2 | heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases | MERCK PATENT GMBH (DE) | 2011-05-24 | — | — | US | claimed |
| US-20080214586-A1 | 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators | MERCK PATENT GMBH (DE) | 2008-09-04 | — | — | US | claimed |
| CN-101180278-A | 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators | MERCK PATENT GMBH (DE) | 2008-05-14 | — | — | CN | claimed |
| EP-1881965-A1 | 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS | Merck Patent GmbH (DE) | 2008-01-30 | — | — | EP | claimed |
| WO-2006122631-A1 | 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2006-11-23 | — | — | WO | claimed |
| US-7947696-B2 | heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases | MERCK PATENT GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| CN-101180278-B | 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators | MERCK PATENT GMBH | 2011-05-04 | — | — | CN | disclosed |
| US-20080214586-A1 | 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators | MERCK PATENT GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| CN-101180278-A | 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators | MERCK PATENT GMBH (DE) | 2008-05-14 | — | — | CN | disclosed |
| EP-1881965-A1 | 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS | Merck Patent GmbH (DE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006122631-A1 | 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214586-A1 | 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators | HSP90AB2P, HSP90AB1, HSP90AA1 | MEN1 4729/4885KMT2A 2946/4885KCNK3 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.